⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9901730 | 0.67 | — | — | |
| SCHEMBL4639177 | 0.67 | — | — | |
| SCHEMBL1822153 | 0.67 | — | — | |
| SCHEMBL19209088 | 0.62 | — | — | |
| SCHEMBL9667836 | 0.62 | — | — | |
| SCHEMBL18414782 | 0.60 | — | — | |
| SCHEMBL967581 | 0.59 | — | — | |
| SCHEMBL12516575 | 0.57 | — | — | |
| SCHEMBL6269826 | 0.57 | — | — | |
| SCHEMBL8036160 | 0.55 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113621005-A | alpha-D-galactoside inhibitors of galectins | 格莱克特生物技术公司 | 2021-11-09 | — | — | CN | disclosed |
| EP-3894392-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER | Duke University (US) | 2021-10-20 | — | — | EP | disclosed |
| CN-107406478-B | alpha-D-galactoside inhibitors of galectins | 格莱克特生物技术公司 | 2021-07-27 | — | — | CN | disclosed |
| WO-2020123675-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER | DUKE UNIVERSITY (US) | 2020-06-18 | — | — | WO | disclosed |
| EP-3250581-A1 | ALPHA-D-GALACTOSIDE INHIBITORS OF GALECTINS | Galecto Biotech AB (DK) | 2017-12-06 | — | — | EP | disclosed |
| WO-2016120403-A1 | ALPHA-D-GALACTOSIDE INHIBITORS OF GALECTINS | GALECTO BIOTECH AB (DK) | 2016-08-04 | — | — | WO | disclosed |
| US-9255090-B2 | Heterocyclyl derivatives and their use as prostaglandin D2 receptor modulators | ACTELION PHARMACEUTICALS LTD. (CH) | 2016-02-09 | — | — | US | disclosed |
| US-20150252036-A1 | Heterocyclyl Derivatives and their use as Prostaglandin D2 Receptor Modulators | IDORSIA PHARMACEUTICALS LTD (CH) | 2015-09-10 | — | — | US | disclosed |
| EP-2670738-A2 | 1,4 OXAZINES AS BACE1 AND/OR BACE2 INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2013-12-11 | — | — | EP | disclosed |
| EP-2665713-A1 | 1,4 OXAZINES AS BACE1 AND/OR BACE2 INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2013-11-27 | — | — | EP | disclosed |
| US-20120323001-A1 | BACE INHIBITORS | ELI LILLY AND COMPANY (US) | 2012-12-20 | — | — | US | disclosed |
| US-8278441-B2 | BACE inhibitors | ELI LILLY AND COMPANY (US) | 2012-10-02 | — | — | US | disclosed |
| WO-2012104263-A2 | 1,4 OXAZINES AS BACE1 AND/OR BACE2 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-08-09 | — | — | WO | disclosed |
| WO-2012098064-A1 | 1,4 OXAZINES AS BACE1 AND/OR BACE2 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-07-26 | — | — | WO | disclosed |
| US-20110009395-A1 | BACE INHIBITORS | ELI LILLY AND COMPANY (US) | 2011-01-13 | — | — | US | disclosed |